查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873335

全球移植用HLA型檢測市場

HLA Typing for Transplant
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到2030年，全球用於移植的HLA型檢測市場規模將達到15億美元。

2024年全球用於移植的HLA型檢測市場規模預計為11億美元，預計到2030年將達到15億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為5.3%。本報告分析的非分子檢測技術細分市場預計將以4.4%的複合年成長率成長，並在分析期間結束時達到8.691億美元。分子檢測技術細分市場預計在分析期間將以6.7%的複合年成長率成長。

美國市場規模估計為2.96億美元，而中國市場預計將以5.1%的複合年成長率成長。

預計到2024年，美國移植HLA型檢測市場規模將達2.96億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到2.329億美元，在2024年至2030年的分析期內，年複合成長率（CAGR）為5.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的年複合成長率分別為5.1%和4.3%。在歐洲，德國的年複合成長率預計約為4.6%。

全球移植HLA型檢測市場－主要趨勢與促進因素摘要

HLA型檢測是器官移植成功的關鍵嗎？

人類白血球抗原（ HLA型檢測是器官移植的基石技術，但為什麼這個基因配對過程對移植成功如此關鍵？ HLA型檢測可以識別白血球表面的特定抗原，這些抗原在免疫系統區分自身和非自身方面發揮關鍵作用。這些抗原對於器官和組織的相容性至關重要，不匹配會導致移植器官排斥。在移植手術中， HLA型檢測確保捐贈者和受體之間盡可能高的免疫相容性，從而降低器官排斥的風險並提高移植器官的存活率。

HLA型檢測的優點在於能夠精準匹配供體和受體的免疫特徵，從而降低急性或慢性排斥等併發症。這不僅對固態器官移植（腎臟、肝臟、心臟和肺臟）至關重要，對造血幹細胞移植（骨髓）也同樣重要，因為在造血幹細胞移植中，精準的HLA配型對於預防移植物抗宿主疾病（GVHD）至關重要。透過了解患者的HLA特徵並找到最佳捐贈者，移植專家可以提高移植成功率，並幫助患者避免可能損害移植器官的免疫反應。隨著器官移植需求的成長和技術的進步， HLA型檢測仍然是這個拯救生命的醫學領域中最佳療效的關鍵工具。

移植領域HLA型檢測技術有哪些進展？

技術進步顯著提高了HLA型檢測的準確性、速度和可及性，使移植供體-受體匹配過程更加高效精準。其中一個最重要的進展是分子技術的引入，特別是基於聚合酵素鏈鎖反應（PCR）的方法和次世代定序（NGS）。傳統上，血清學檢測用於鑑定HLA抗原，但其檢測細微突變和實現高解析度分型的能力有限。 PCR和NGS技術的出現極大地提高了HLA型檢測的解析度和準確性，能夠識別僅相差幾個鹼基對的特定等位基因，這對於精細調整供體-受體相容性至關重要。

次世代定序（ NGS）透過提供高通量、全面的HLA基因訊息，徹底革新了HLA型檢測。 NGS能夠並行定序多個HLA基因，使移植團隊能夠更詳細地了解供體和受體的HLA等位基因。這種高解析度分型在造血幹細胞移植中尤其重要，因為即使是基因層面的微小錯配也可能導致移植物抗宿主疾病等嚴重併發症。 NGS的另一個優點在於能夠識別傳統方法難以檢測到的罕見和新型等位基因，從而進一步提高捐贈者選擇的準確性，並降低排斥反應和免疫併發症的風險。

HLA型檢測的另一項重大進展是應用了新一代交叉配型檢測技術，有助於評估抗體介導排斥反應的可能性。這些檢測採用先進的流式細胞技術和Luminex技術來檢測受者血液中的供體特異性抗體（DSA）。 DSA是抗體介導排斥反應的主要風險因素，高解析度HLA型檢測結合詳細的交叉配對，使移植團隊能夠更準確地評估排斥風險，並根據患者的需求制定個人化的免疫抑制治療方案。這些交叉配型技術使得移植計畫的發展更加靈活，從而降低了移植失敗的風險，並改善了長期預後。

高解析度HLA型檢測也受惠於軟體工具和生物資訊學平台的進步，這些進步使得序列資料的解讀更加快速且準確。先進的演算法能夠即時分析大量的序列數據，使移植中心能夠快速匹配供體和受體。這些平台不僅加快了流程，還降低了人為錯誤的機率，提高了HLA匹配的可靠性。此外，生物資訊學工具還能辨識HLA抗原決定位錯配——HLA分子中可能引發免疫反應的微小差異——從而實現供體和受體之間更精確的匹配。

人工智慧 (AI) 和機器學習的興起是改變HLA型檢測的另一個領域。人工智慧驅動的系統正在開發中，透過分析大量的 HLA 譜和移植結果資料集，更有效地預測供體-受體相容性。這些系統模擬不同 HLA 匹配之間潛在的免疫反應，有助於最佳化捐贈者選擇並降低排斥風險。透過利用預測分析，人工智慧最終可能使移植中心能夠進一步改進其 HLA 匹配演算法，即使在無法實現完美 HLA 匹配的情況下，也有可能提高移植成功率。

快速HLA型檢測技術的進步也使得緊急移植病例能夠及時進行配型。在患者病情迅速惡化的情況下，傳統的HLA型檢測方法耗時過長，可能無法確保移植成功。然而，基於PCR的快速技術現在可以在數小時內而非數天內提供HLA型檢測結果，從而在緊急情況下實現更快的配型。這對於肝臟、心臟和肺移植尤其重要，因為時間至關重要，患者需要緊急手術。

最後，用於活體捐贈者移植的HLA型檢測技術的進步正在提高腎臟移植等手術的安全性和成功率。透過提高活體供體和受體之間的相容性， HLA型檢測降低了慢性排斥的風險，從而改善了供體和受體的長期預後。此外，快速且準確的HLA型檢測也提高了腎臟交換計畫的效率，在腎臟交換計畫中，活體捐贈者交換腎臟以尋找更佳的HLA匹配，使更多患者能夠找到合適的捐贈者，同時降低排斥風險。

為什麼HLA型檢測對器官移植的成功至關重要？

HLA型檢測對於器官移植的成功至關重要，因為它在決定捐贈器官和組織能否被受體免疫系統接受方面起著核心作用。細胞表面的HLA分子將外來物質呈現給免疫系統，一旦偵測到不匹配，就會引發免疫反應。在器官移植中，如果供體的HLA抗原與受體的HLA抗原有顯著差異，受體的免疫系統可能會將器官識別為外來物並發動攻擊，導致急性或慢性排斥反應。因此，準確的HLA型檢測有助於更精確地匹配供體和受體，最大限度地降低排斥反應的風險，並確保移植器官的長期存活。

在腎臟移植中， HLA型檢測已被證實對移植結果有顯著影響。接受HLA高度匹配器官的患者，其排斥率往往較低，移植器官存活時間較長，而接受HLA匹配度較低的器官的患者則不然。這一點對於「高度致敏」的患者尤其重要，因為他們可能由於先前移植、懷孕或輸血而獲得了針對HLA抗原的抗體。雖然為這些患者尋找匹配的供體更具挑戰性，但精準的HLA型檢測結合脫敏通訊協定，可以幫助確保獲得匹配的器官，並降低抗體介導的排斥反應風險。

在造血幹細胞移植（HSCT）中，HLA相容性尤其重要。供體和受體HLA等位基因不匹配會導致移植物抗宿主疾病（GVHD），這是一種可能危及生命的疾病，移植的免疫細胞會攻擊受體本身的組織。由於即使是HLA等位基因的輕微不匹配也可能導致嚴重的GVHD，因此找到完全或近乎完全匹配的HLA匹配對於降低這種併發症的風險至關重要。高解析度HLA型檢測在HSCT中至關重要，因為它能夠精確匹配主要HLA位點（例如HLA-A、HLA-B、HLA-C和HLA-DRB1）和次要位點。因此， HLA型檢測有助於預防移植幹細胞的排斥反應以及GVHD等嚴重併發症。

HLA型檢測對於肝臟、心臟和肺移植的成功至關重要。然而，這些移植對HLA匹配的要求可能不如腎臟移植或造血幹細胞移植（HSCT）嚴格。在這些情況下，其他因素，例如ABO血型相容性和器官大小相容性，也同樣重要。但是，研究表明，更好的HLA匹配仍然可以透過降低排斥風險和提高長期移植存活率來改善預後。良好的HLA匹配可以顯著影響長期存活率，尤其是在心臟和肺移植中，因為這些移植的捐贈器官稀缺，且存活率低於腎臟移植。

在活體器官移植（例如腎臟移植）中， HLA型檢測能夠幫助移植團隊最佳化捐贈者之間的匹配度，從而提高移植成功率。在活體腎臟捐贈中， HLA型檢測用於確定捐贈者的匹配度。當無法找到完全匹配的捐贈者時， HLA型檢測也可以用於促進腎臟交換配對。這使得活體器官移植方案更加靈活，增加了潛在的匹配數量，使患者能夠更快地接受移植。通常情況下，活體器官的HLA匹配度會優於已故捐贈者器官。

除了器官和幹細胞移植之外， HLA型檢測在輸血醫學中也發揮著至關重要的作用，因為HLA不匹配會導致輸血相關反應，例如輸血相關性急性肺損傷（TRALI）。在血小板輸注中， HLA型檢測透過HLA抗體配對患者和供者，確保輸血的安全性和有效性。由國家骨髓捐贈者計劃等機構營運的骨髓庫利用HLA型檢測來識別需要幹細胞移植的患者的潛在供者，從而顯著提高找到匹配供者的幾率。

HLA型檢測不僅對移植手術的即時成功至關重要，而且對受者的長期健康至關重要。 HLA配對不佳會導致慢性排斥反應，這是一個緩慢進行性的過程，最終會導致移植器官衰竭。慢性排斥反應是長期移植失敗的主要原因之一，尤其是在腎臟和心臟移植。透過提高捐贈者和受者之間的HLA配對，移植中心可以降低慢性排斥反應的發生率，並確保移植器官在受者有生之年，或至少在未來許多年內持續發揮作用。

哪些因素正在推動移植HLA型檢測市場的成長？

移植HLA型檢測市場的成長受多種關鍵因素驅動，包括器官和幹細胞移植需求的不斷成長、 HLA型檢測技術的進步、慢性病盛行率的上升以及全球移植登記庫的擴容。其中一個關鍵促進因素是器官移植需求的不斷成長，這主要是由於末期腎功能衰竭（ESRD）、肝功能衰竭、心臟衰竭和血液癌症等疾病的發生率不斷上升所致。隨著移植等待名單上的患者人數持續增加，對準確高效的HLA型檢測以匹配供體和受體的需求也相應成長。

HLA型檢測技術的進步，特別是次世代定序（NGS）技術的引入，也推動了市場成長。 NGS技術使高解析度HLA型檢測更加精準、快速且經濟高效，成為移植中心降低排斥風險、最佳化治療效果的首選方法。高精度定序整個HLA區域的能力提高了供體選擇標準，並提升了移植成功率，尤其是在高度致敏患者和涉及罕見HLA等位基因的複雜病例中。隨著越來越多的移植中心採用NGS進行HLA型檢測，預計對這些高解析度技術的需求將會增加，從而推動市場擴張。

糖尿病、高血壓和癌症等慢性疾病的日益普及也是推動HLA型檢測市場成長的因素之一。這些疾病是導致器官衰竭的主要原因，尤其是腎臟、肝臟和心臟衰竭。隨著這些疾病在全球的負擔持續加重，需要器官移植的患者人數也不斷增加。 HLAHLA型檢測對於確保這些患者獲得相容的器官或幹細胞至關重要，它能夠改善移植效果，並減少因排斥或移植失敗而需要再次移植的情況。

骨髓和器官捐贈者登記庫的擴充也是HLA型檢測市場成長的主要驅動力。諸如美國的「Be The Match」組織和國際登記庫等機構正致力於增加HLA型檢測捐贈者的數量，尤其是在造血幹細胞移植領域。隨著越來越多的人登記成為潛在捐贈者，對快速、準確的HLA型檢測以尋找匹配捐贈者的需求也隨之增加。特別是，幹細胞移植志願捐贈者的增加，使得對高解析度HLA型檢測的需求顯著成長，因為精準配型對於降低移植物抗宿主疾病等併發症的風險至關重要。

對精準醫療和個人化醫療日益成長的關注也是推動市場成長的因素之一。 HLAHLA型檢測是移植領域個人化治療的核心，它能將每位患者獨特的基因組成與最合適的捐贈者配對，從而確保最佳的治療效果。基因組學的進步以及分子診斷在移植醫學中的應用，使得人們更加關注個人化治療方案，包括基於HLA不相容程度的個人化免疫抑制療法。這種向精準醫療的轉變預計將進一步擴大HLA型檢測服務的需求。

政府推行的促進器官捐贈和移植的措施以及相關的醫療政策，也推​​動了HLA型檢測市場的成長。許多國家都在投資公共衛生宣傳活動，旨在意識提升，並改善移植基礎設施。此外，器官移植的法規結構和報銷政策也日趨完善，使患者更容易獲得挽救生命的移植手術。隨著需要移植的患者人數不斷增加，政府和醫療系統加強支持力度，預計將進一步刺激HLA型檢測的需求。

最後，交叉配對試驗的進步，例如利用Luminex和流式細胞技術檢測供體特異性抗體（DSA），正在推動對全面的HLA型檢測和交叉配對通訊協定的需求。這些技術使移植團隊能夠更準確地評估抗體介導的排斥反應風險，從而實現供體和受體更精準的配型，進而改善移植結果。交叉配對試驗與高解析度HLA型檢測的日益普及，提高了移植器官的長期存活率，進一步推動了市場成長。

隨著器官和幹細胞移植需求的不斷成長、 HLA型檢測技術的進步以及全球精準醫療的興起， HLA型檢測市場預計將顯著成長。在醫療系統持續將移植成功率和患者預後放在首位的情況下， HLA型檢測仍將是確保捐贈者相容性、降低排異風險以及提高移植受者長期存活率的關鍵工具。

部分：

技術（非分子檢測、分子檢測）、產品和服務（試劑和耗材、設備、軟體和服務）、應用（診斷、研究）

受訪公司範例

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Global Industry Analysts 並沒有依賴通用的 LLM 或查詢產業專用的SLM，而是建立了一個由世界各地領域專家精心整理的內容庫，包括視訊轉錄、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

我們最新發布的報告納入了關稅對區域市場的影響，正如全球產業分析師預測的那樣，關稅將改變企業的競爭地位，而企業的競爭地位將取決於其總部所在地、製造地以及進出口（成品和OEM產品）。這種複雜多變的市場現實將透過微觀和宏觀市場動態影響競爭對手，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP12411

Global HLA Typing for Transplant Market to Reach US$1.5 Billion by 2030

The global market for HLA Typing for Transplant estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Molecular Assay Technology, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$869.1 Million by the end of the analysis period. Growth in the Molecular Assay Technology segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 5.1% CAGR

The HLA Typing for Transplant market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$232.9 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.1% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global HLA Typing for Transplant Market - Key Trends and Drivers Summarized

Is HLA Typing the Key to Success in Organ Transplantation?

HLA typing, or human leukocyte antigen typing, is a cornerstone of organ transplantation, but why is this genetic matching process so vital for transplant success? HLA typing involves identifying specific antigens on the surface of white blood cells that play a critical role in the immune system’s ability to recognize self from non-self. These antigens are crucial in organ and tissue compatibility, as mismatches can lead to rejection of the transplanted organ. In transplantation, HLA typing ensures that the donor and recipient are as immunologically compatible as possible, reducing the risk of organ rejection and improving graft survival.

The appeal of HLA typing lies in its ability to match the donor’s and recipient’s immune profiles closely, reducing complications such as acute or chronic rejection. It is essential not only for solid organ transplants (kidneys, liver, heart, lungs) but also for hematopoietic stem cell transplants (bone marrow), where precise HLA matching is critical to prevent graft-versus-host disease (GVHD). By understanding the patient’s HLA profile and finding the best donor match, transplant specialists can improve the success rates of transplants and help patients avoid the immune responses that might otherwise compromise the graft. As the demand for organ transplants grows and technology advances, HLA typing remains a critical tool for achieving the best possible outcomes in this life-saving medical field.

How Has Technology Advanced HLA Typing for Transplantation?

Technological advancements have significantly improved the accuracy, speed, and accessibility of HLA typing, transforming it into a more efficient and precise process for matching donors and recipients in transplantation. One of the most important developments has been the introduction of molecular techniques, particularly polymerase chain reaction (PCR)-based methods and next-generation sequencing (NGS). In the past, serological testing was used to identify HLA antigens, but these methods had limitations in detecting subtle variations and providing high-resolution typing. The shift to PCR and NGS has dramatically improved the resolution and accuracy of HLA typing, allowing for the identification of specific alleles that differ by only a few nucleotides, which can be critical in fine-tuning donor-recipient compatibility.

Next-generation sequencing has revolutionized HLA typing by providing high-throughput, comprehensive genetic information about HLA loci. NGS allows for the sequencing of multiple HLA genes in parallel, giving transplant teams a more detailed understanding of both donor and recipient HLA alleles. This high-resolution typing is particularly important in hematopoietic stem cell transplants, where even small mismatches at the genetic level can lead to serious complications like graft-versus-host disease. NGS also has the advantage of identifying rare or novel alleles that might not be detectable with older methods, further enhancing the precision of donor selection and reducing the risk of rejection or immune complications.

Another major advancement in HLA typing is the use of next-generation crossmatch assays, which help assess the potential for antibody-mediated rejection. These assays use advanced flow cytometry and Luminex technology to detect donor-specific antibodies (DSAs) in the recipient’s blood. DSAs are a major risk factor for antibody-mediated rejection, and by combining high-resolution HLA typing with detailed crossmatch testing, transplant teams can more accurately assess the risk of rejection and tailor immunosuppressive therapies to the patient’s needs. These crossmatch technologies allow for a more dynamic approach to transplant planning, reducing the likelihood of graft loss and improving long-term outcomes.

High-resolution HLA typing has also benefited from advances in software tools and bioinformatics platforms, which enable faster, more accurate interpretation of sequencing data. Sophisticated algorithms can now analyze large volumes of sequencing data in real time, ensuring that transplant centers can quickly match donors and recipients. These platforms not only speed up the process but also reduce the likelihood of human error, improving the reliability of HLA matching. Additionally, bioinformatics tools can identify HLA epitope mismatches-small differences in HLA molecules that might trigger an immune response-allowing for even more refined matching between donors and recipients.

The rise of artificial intelligence (AI) and machine learning is another area transforming HLA typing. AI-driven systems are being developed to predict donor-recipient compatibility more effectively by analyzing large datasets of HLA profiles and transplant outcomes. These systems can model the potential immune responses between different HLA matches, helping to optimize donor selection and reduce the risk of rejection. By leveraging predictive analytics, AI could eventually allow transplant centers to refine HLA matching algorithms further, improving transplant success rates even in cases where perfect HLA matches are not available.

Advances in rapid HLA typing methods have also made it possible to provide timely matches for urgent transplant cases. In cases where a patient’s condition deteriorates quickly, traditional methods of HLA typing may take too long to ensure a successful transplant. However, rapid PCR-based techniques can now provide HLA typing results in a matter of hours rather than days, allowing for faster matching in emergency situations. This is particularly important in liver, heart, or lung transplants, where time is of the essence and patients are often in critical need of immediate surgery.

Finally, advancements in HLA typing for living donor transplants have improved the safety and success of procedures such as kidney transplants. By ensuring a closer match between living donors and recipients, HLA typing has reduced the risk of chronic rejection, leading to better long-term outcomes for both donor and recipient. Additionally, paired kidney exchanges, where living donors swap kidneys to find better HLA matches, have been made more effective through rapid and precise HLA typing, helping more patients find suitable donors while maintaining low rejection risks.

Why Is HLA Typing Critical for Successful Organ Transplants?

HLA typing is critical for successful organ transplants because it plays a central role in determining whether a donor’s organ or tissue will be accepted by the recipient’s immune system. The HLA molecules on the surface of cells are responsible for presenting foreign substances to the immune system, triggering an immune response if a mismatch is detected. In organ transplantation, if the donor’s HLA antigens are too different from the recipient’s, the recipient’s immune system may recognize the organ as foreign and mount an attack, leading to acute or chronic rejection. Therefore, accurate HLA typing helps match donors and recipients more precisely, minimizing the risk of rejection and ensuring long-term graft survival.

In kidney transplantation, HLA typing has been shown to significantly influence graft outcomes. Patients with a high degree of HLA matching tend to experience fewer rejection episodes, and their grafts tend to last longer compared to patients with poorly matched organs. This is especially important in highly sensitized patients-those who have developed antibodies against HLA antigens due to prior transplants, pregnancies, or blood transfusions. For these patients, finding a well-matched donor is more challenging, but precise HLA typing, combined with desensitization protocols, can help them receive compatible organs and reduce the risk of antibody-mediated rejection.

In hematopoietic stem cell transplants (HSCT), HLA matching is even more critical. Mismatches between donor and recipient HLA alleles can lead to graft-versus-host disease (GVHD), a potentially life-threatening condition where the transplanted immune cells attack the recipient’s tissues. Even minor mismatches in HLA alleles can result in severe GVHD, so finding a perfect or near-perfect HLA match is essential for reducing the risk of this complication. High-resolution HLA typing is crucial in HSCT to ensure that both the major HLA loci (such as HLA-A, HLA-B, HLA-C, and HLA-DRB1) and minor loci are carefully matched. As a result, HLA typing helps prevent both rejection of the transplanted stem cells and serious complications like GVHD.

HLA typing is also essential for the success of liver, heart, and lung transplants, although the level of HLA matching required for these transplants may not be as strict as for kidney or HSCT. In these cases, other factors like ABO blood type matching and organ size compatibility are also important. However, research has shown that better HLA matching can still improve outcomes by reducing the risk of rejection and improving graft longevity. In particular, for heart and lung transplants, where donor organs are scarce and survival rates are lower than in kidney transplants, achieving a good HLA match can significantly impact long-term survival.

For living donor transplants, such as in kidney transplantation, HLA typing enables transplant teams to optimize the match between donors and recipients, improving the likelihood of success. In living kidney donation, HLA typing is used to determine the compatibility between donor and recipient, and in some cases, where a perfect match is not available, HLA typing is used to facilitate paired kidney exchanges. This allows for a more flexible approach to living donor transplants, increasing the number of possible matches and helping patients receive transplants sooner, often with better HLA matches than deceased donor organs.

Beyond organ and stem cell transplantation, HLA typing also plays a critical role in transfusion medicine, where HLA mismatches can cause transfusion-related reactions such as transfusion-related acute lung injury (TRALI). In platelet transfusions, HLA typing is used to match donors with patients who have developed HLA antibodies, ensuring that transfusions are safer and more effective. In bone marrow registries, such as those run by organizations like the National Marrow Donor Program, HLA typing is used to identify potential donors for patients in need of stem cell transplants, significantly improving the chances of finding compatible matches.

HLA typing is not only important for the immediate success of the transplant but also for the long-term health of the recipient. Poor HLA matching can lead to chronic rejection, a slow and progressive process that eventually causes the transplanted organ to fail. Chronic rejection is one of the leading causes of late graft loss, particularly in kidney and heart transplants. By improving the HLA match between donor and recipient, transplant centers can reduce the likelihood of chronic rejection, ensuring that the transplant remains functional for many years, if not for the lifetime of the recipient.

What Factors Are Driving the Growth of the HLA Typing for Transplant Market?

The growth of the HLA typing for transplant market is driven by several key factors, including the rising demand for organ and stem cell transplants, advancements in HLA typing technologies, the increasing prevalence of chronic diseases, and the expansion of transplant registries worldwide. One of the primary drivers is the growing need for organ transplants, fueled by the rising incidence of conditions such as end-stage renal disease (ESRD), liver failure, heart failure, and hematological cancers. As the number of patients waiting for transplants continues to rise, the demand for accurate and efficient HLA typing to match donors and recipients has grown correspondingly.

Advancements in HLA typing technologies, particularly the adoption of next-generation sequencing (NGS), have also contributed to market growth. NGS has made high-resolution HLA typing more accurate, faster, and cost-effective, making it the preferred method for transplant centers seeking to minimize rejection risks and optimize outcomes. The ability to sequence entire HLA regions with high precision has improved donor selection and increased the success rates of transplants, particularly in complex cases involving highly sensitized patients or rare HLA alleles. As more transplant centers adopt NGS for HLA typing, the demand for these high-resolution techniques is expected to increase, driving market expansion.

The increasing prevalence of chronic diseases, such as diabetes, hypertension, and cancer, is another factor contributing to the growth of the HLA typing market. These conditions are leading causes of organ failure, particularly for kidneys, livers, and hearts. As the global burden of these diseases continues to rise, so does the number of patients requiring transplants. HLA typing is essential for ensuring that these patients receive compatible organs or stem cells, improving transplant outcomes and reducing the need for re-transplantation due to rejection or graft failure.

The expansion of bone marrow and organ donor registries is also playing a significant role in driving the HLA typing market. Organizations such as Be The Match in the United States and international registries are working to increase the number of HLA-typed donors, particularly for hematopoietic stem cell transplants. As more individuals register as potential donors, the need for rapid and accurate HLA typing to identify matches grows. In particular, the rise of volunteer donors for stem cell transplants has created a significant demand for high-resolution HLA typing, as precise matching is critical for reducing the risk of complications like graft-versus-host disease.

The growing emphasis on precision medicine and personalized healthcare is another factor driving market growth. HLA typing is central to the personalized approach in transplantation, where each patient’s unique genetic makeup must be matched to the most suitable donor to ensure the best possible outcome. Advances in genomics and the integration of molecular diagnostics in transplant medicine have increased the focus on individualized treatment plans, which include tailored immunosuppressive regimens based on the degree of HLA mismatch. This shift toward precision medicine is expected to further expand the demand for HLA typing services.

Government initiatives and healthcare policies promoting organ donation and transplantation are also contributing to the growth of the HLA typing market. Many countries are investing in public health campaigns to raise awareness about organ donation and improve the infrastructure for transplantation. Additionally, regulatory frameworks and reimbursement policies for organ transplants are becoming more favorable, making it easier for patients to access life-saving transplant procedures. This increased support from governments and healthcare systems is expected to drive further growth in the demand for HLA typing as more patients are referred for transplantation.

Finally, advancements in crossmatch testing, including the use of Luminex and flow cytometry techniques to detect donor-specific antibodies (DSAs), are driving demand for comprehensive HLA typing and crossmatching protocols. These techniques allow transplant teams to assess the risk of antibody-mediated rejection more accurately, improving transplant outcomes by enabling more precise donor-recipient matching. The increasing use of crossmatch testing, combined with high-resolution HLA typing, is leading to better long-term graft survival rates, further supporting market growth.

With the increasing need for organ and stem cell transplants, technological advancements in HLA typing, and the global shift toward precision medicine, the HLA typing market is poised for significant growth. As healthcare systems continue to prioritize transplant success and patient outcomes, HLA typing will remain a critical tool for ensuring compatibility, reducing rejection risks, and improving the long-term survival of transplant recipients.

SCOPE OF STUDY:

The report analyzes the HLA Typing for Transplant market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Non-Molecular Assay, Molecular Assay); Products & Services (Reagents & Consumables, Instruments, Software & Services); Application (Diagnostics, Research)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Affymetrix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • HLA Typing for Transplant - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Organ Transplantation Drives Growth in HLA Typing Market
    • Expansion of Bone Marrow and Stem Cell Transplant Programs Spurs Adoption of HLA Typing for Transplantation
    • Role of HLA Typing in Supporting Research on Immunotherapy and Autoimmune Diseases Expands Market Reach
    • Role of HLA Typing in Enhancing Success Rates in Kidney and Liver Transplants Fuels Market Growth
    • Growth in Use of HLA Typing in Allogeneic and Autologous Transplantation Strengthens Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Non-Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Non-Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Molecular Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Molecular Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World HLA Typing for Transplant Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for HLA Typing for Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • JAPAN
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • CHINA
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • EUROPE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for HLA Typing for Transplant by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for HLA Typing for Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • GERMANY
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • HLA Typing for Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for HLA Typing for Transplant by Products & Services - Reagents & Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for HLA Typing for Transplant by Products & Services - Percentage Breakdown of Value Sales for Reagents & Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for HLA Typing for Transplant by Technology - Non-Molecular Assay and Molecular Assay Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for HLA Typing for Transplant by Technology - Percentage Breakdown of Value Sales for Non-Molecular Assay and Molecular Assay for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for HLA Typing for Transplant by Application - Diagnostics and Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for HLA Typing for Transplant by Application - Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for HLA Typing for Transplant by Application - Percentage Breakdown of Value Sales for Diagnostics and Research for the Years 2015, 2025 & 2030

IV. COMPETITION